Justin Baldoni is asking the court to shut down Blake Lively’s lawsuit in its entirety. New filings obtained by Page Six show that the 41-year-old actor has requested a full dismissal, arguing that “no reasonable jury” would find him liable when the case goes to trial in March 2026.
In his motion, Baldoni claims Lively has no evidence to support her accusations, which include sexual harassment, retaliation, defamation, and conspiracy. He also argues that she was “an independent contractor, not an employee,” pushing back on claims tied to alleged contract violations.
The Jane the Virgin actor disputes the sweeping financial damages Lively outlined in her original complaint, describing them as speculative and unsupported by any proof. Lively alleged her losses totaled $161 million. Her breakdown included $56.2 million in lost career earnings and endorsements, another $49 million in damages to her haircare brand Blake Brown, and $22 million in losses connected to her beverage business, Betty Buzz and Betty Booze.
She also asserted that her reputation suffered a $34 million hit after 65 million negative online impressions about her appeared. Baldoni argues that those numbers are inflated and impossible to verify. He says her claims for lost profits “lack standing” and are “speculative, possible, or imaginary.”
Lively filed her lawsuit in December 2024, accusing Baldoni of sexual harassment and retaliation during production of It Ends With Us. Baldoni has denied all accusations since the beginning and responded by filing a $400 million countersuit for defamation in January 2025. His countersuit was dismissed earlier this year.
The two sides remain deeply divided, and the filings make clear that neither intends to back down. Baldoni’s request for a full dismissal signals a push to end the case long before it reaches a jury, while Lively stands by her claims and the extensive financial losses she says she suffered.
The judge has not yet ruled on Baldoni’s motion. The outcome will determine whether the case moves forward into what is expected to be a high-profile trial next spring.